Target for anti-cancer drug has extensive features than what its name suggests.

Drugs that inhibit the activity of the enzyme called histone deacetylase （ Hdac) widely in cancer and the market already two other diseases to treat has been developed. Perelman medical researcher, University of Pennsylvania (Abramson Cancer Center to house), so this suggests re-evaluation of the molecular targets of the justification for this kind of drug, when abolished the enzymatic activity in the mouse indicates major HDAC function a beneficial effect of the HDAC Inhibitors may not be actually HDAC activity inhibits.

View the original article here